328
Participants
Start Date
December 31, 2015
Primary Completion Date
September 30, 2020
Study Completion Date
December 31, 2022
Acelarin
825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Gemcitabine
1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Cancer Research UK Liverpool Cancer Trials Unit, Liverpool
Collaborators (1)
Cancer Research UK
OTHER
University of Liverpool
OTHER
The Clatterbridge Cancer Centre NHS Foundation Trust
OTHER